Zenosense, Inc. – Hospital Collaboration – 400 Person Lung Cancer Detection Trial

VALENCIA, SPAIN–(Marketwired – Dec 17, 2014) – Zenosense, Inc. ( OTCQB : ZENO ) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, is pleased to announce that on 16 December 2014, the Company’s development…

Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible

VALENCIA, SPAIN–(Marketwired – Dec 4, 2014) – Zenosense, Inc. ( OTCQB : ZENO ) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, is pleased to announce that Depository Trust Corporation (DTC) has approved Zenosense…

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

VALENCIA, SPAIN–(Marketwired – Nov 4, 2014) – Zenosense, Inc. ( OTCQB : ZENO ) (“Zenosense,” the “Company”), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, is pleased to announce the manufacturing of a pre-commercial prototype device to…

Zenosense, Inc.; MRSA/SA Prototype Achieves over 95% Sensibility in Cultured Headspace

VALENCIA, SPAIN / ACCESSWIRE / Ocotber 27, 2014 / Zenosense, Inc. (ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, is pleased to announce considerable progress made in the development of its MRSA/SA detector.…

Zenosense, Inc. Highlights Recent Media Coverage of MRSA

VALENCIA, SPAIN–(Marketwired – May 27, 2014) – Zenosense, Inc. ( OTCQB : ZENO ) (“Zenosense”, the “Company”), a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug,” notes a number of recent and relevant articles in the media…

Zenosense, Inc. Provides Development Update

VALENCIA, SPAIN–(Marketwired – May 21, 2014) – Zenosense, Inc. ( OTCQB : ZENO ) (“Zenosense”, the “Company”), a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug,” is pleased to announce that based on data and information provided…

Zenosense, Inc. Launches New Company Website

VALENCIA, SPAIN–(Marketwired – Apr 3, 2014) – Zenosense, Inc. ( OTCQB : ZENO ) (the “Company”), a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug,” is pleased to announce that the new Company website is now online.…